Perlmutter Cancer Center

The purpose of the study is to determine the safety, tolerability, and efficacy of tisotumab vedotin compared to chemotherapy in participants with recurrent/metastatic cervical cancer (r/mCC) who have received 1 or 2 prior lines of systemic therapy. Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). The study drug Tisotumab vedotin is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.